



DAFTAR PUSTAKA

- Al-Attas, S.A., Amro, S.O., 2010. Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients. *Medical Saudi*. 30, 101–108.
- Alexander, M., Bloom, B.R., Hopwood, D.A., Hull, R., Iglewski, B.H., Laskin, A.I., *et al.*, 2000. *Encyclopedia of Microbiology*, Four-Volume. Second Edition. *Academic Press*, New York. 1132-1145
- Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., Pitula, A., 2004. Development and characterization of an in vivo central venous catheter *Candida albicans* biofilm model. *Infection Immunology*. 72, 6023–6031.
- Ashley, E.S.D., Lewis, R., Lewis, J.S., Martin, C., Andes, D., 2006. *Pharmacology of Systemic Antifungal Agents*. *Clinical Infection Disease*. 43
- Barros, M.E.S.B., Freitas, J.C.R., Oliveira, J.M., Da Cruz, C.H.B., da Silva, P.B.N., de Araújo, L.C.C., *et al.*, 2014. Synthesis and evaluation of (–)-massoialactone and analogues as potential anticancer and anti-inflammatory agents. *European Journal of Medicinal Chemistry*, 76, 291–300.
- Bafadal, M., Hertiani, T., Yuswanto, A., 2016. 'Efek Minyak Masoyi (*Massoia aromatic* Becc.) Terhadap Kultur Multispecies Biofilm'. *Tesis*, MSc, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta Indonesia.
- Berman, J., Sudbery, P.E., 2002. *Candida albicans*: a molecular revolution built on lessons from budding yeast. *National Genetica*. Review. 3, 918–930.
- Biswas, S.K., Chaffin, W.L., 2005. Anaerobic growth of *Candida albicans* does not support biofilm formation under similar conditions used for aerobic biofilm. *Current Microbiology*. 51, 100–104.
- Brooks, G. F., Carroll, K.C., Butel, J.S., Morse, S.A., 2007. *Medical Microbiology*, 24th Edition. Editor: Jawetz, Melnick & Adelberg's, *McGraw-Hill Medical*. 654-720.
- Brown, A.J., Gow, N.A., 1999. Regulatory networks controlling *Candida albicans* morphogenesis. *Trends Microbiology*. 7, 333–338.
- Casadevall, A., Pirofski, L.A., 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. *Infection Immunology*. 67, 3703–3713.
- Chaturvedi, D., Mishra, B.B., Tiwari, V.K., 2011. 'Opportunity, challenge and scope of natural products in medicinal chemistry' *Thesis*, Departement of chemistry, faculty of Science, Banaras Hindu Unversoty Vanarasi-221005, India. 102-105.



- Cleary, J.D., Chapman, S.W., Nolan, R.L., 1992. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. *Antimicrobiology Agents Chemother.* 36, 977–981.
- Dan , M., 2009. Efektifitas minyak masoyi (*Massoia aromatica*) terhadap helopeltis antonii sign pada jambu mete dan *Chrysocoris javanus* pada jarak pagar. *Peneliti Tanaman.* 140.
- Ghannoum, M.A., Rice, L.B., 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clinical Microbiology. Review.* 12, 501–517.
- Grubb, S.E.W., Murdoch, C., Sudbery, P.E., Saville, S.P., Lopez-Ribot, J.L., Thornhill, M.H., 2008. *Candida albicans*-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. *Infection Immunology.* 76, 4370– 4377.
- Ha, K.C., White, T.C., 1999. Effects of Azole Antifungal drugs on the transition from yeast Cells to hyphae in susceptible and resistant isolates of the pathogenic yeast *Candida albicans*. *Antimicrobiology Agents Chemother.* 43, 763– 768.
- Haris, R., 1993. *Tanaman Minyak Atsiri.* Cetakan IV. Penerbit Penebar Swadaya, Jakarta.
- Hertiani, T., Pratiwi, S. U. T., Yuswanto, A., Permanasari, P., 2016. Potency of *Massoia* Bark in combating immunosuppressed - related infection. *Pharmacognosy Magazine.* 12.
- Heyne, K., 1950, *Tumbuhan berguna Indonesia*, diterjemahkan dari Bahasa Inggris oleh Badan Penelitian dan Pengembangan Kehutanan,. Yayasan Sarana Wana Jaya : Diedarkan oleh Koperasi Karyawan, Departemen Kehutanan, Jakarta.
- Hidayat, U., Sudarmin, S., Siadi, K., 2012. Uji aktivitas senyawa hasil oksidasi Kariofilena dengan KMnO₄ terhadap *Candida albicans*. *Indonesian Journal Chemical Science.* 1. 3-4.
- Iskandar, M.I. dan Ismanto, A., 1999. Tinjauan beberapa sifat Dan Manfaat Tumbuhan Masoyi (*Massoia Aromaticum Becc.*). *Warta Tumbuhan Obat Indonesia.* 5.
- Jacob M. H., Ellen, C.J., Amber, D.E., 2001. Quorum sensing in the dimorphic fungus *Candida albicans* is mediated by farnesol. *Aplied Enviromental Microbiology.* 2982-2992.
- Jong, A.Y., Stins, M.F., Huang, S.H., Chen, S.H., Kim, K.S., 2001. Traversal of *Candida albicans* across human blood-brain barrier in vitro. *Infection Immunology.* 69, 4536–4544.



- Khan, M.S.A., Ahmad, I., Aqil, F., Owais, M., Shahid, M., Musarrat, J., 2010. Virulence and pathogenicity of fungal pathogens with special reference to *Candida albicans*, combating fungal infections. *Springer Berlin Heidelberg*, Berlin, Heidelberg. 21–45.
- Khanna, N., 2007. *Antimicrobial Agents: Antifungal & Antiviral Drugs*. 2564-2568
- Khishimoto, N., Sugihara, S., Mochida, K., 2005. In vitro antifungal and antiviral activities of γ - and δ -lactone analog utilized as food flavoring. *Biocontrol Science*. 3-5
- Larabi, M., Legrand, P., Appel, M., Gil, S., Lepoivre, M., Devissaguet, J.-P., Puisieux, F., *et al.*, 2001. Reduction of NO synthase expression and tumor necrosis factor alpha production in macrophages by Amphotericin B lipid Carriers. *Antimicrobiology Agents Chemother.* 45, 553–562.
- Lee, W., Lee, D.G., 2014. An antifungal mechanism of curcumin lies in membrane-targeted action within *Candida albicans*. *IUBMB Life*. 1-7
- Lodder, J., Kreger, V.R.N.J.W., 1967. Lodder, J. 1970. The Yeasts: a taxonomic study. *North-Holland Public*. Cambridge, United Kingdom. 3605-3625.
- Madigan, M.T., Martinko, J., Parker, J., 2002. *Brock Biology of Microorganisms*, 10 edition. *Prentice Hall, Upper Saddle River*. 1454.
- Martin, S.W., Douglas, L.M., Konopka, J.B., 2005. Cell cycle dynamics and quorum sensing in *Candida albicans* chlamyospores are distinct from budding and hyphal growth. *Eukaryot Cell*. 4, 1191–1202.
- Mayer, F.L., Wilson, D., Hube, B., 2013. *Candida albicans* pathogenicity mechanisms. *Virulence*. 4, 119–128.
- McGaw, L.J., Lall, N., Meyer, J.J.M., Eloff, J.N., 2008. The potential of South African plants against Mycobacterium infections. *Journal Ethnopharmacol., (Ethnobotany in South Africa)* 119, 482–500.
- Muhlisah, F., 2007. *Tanaman Obat Keluarga (Revisi)*. Niaga Swadaya, Jakarta, Indonesia. 8-10.
- Naglik, J., Albrecht, A., Bader, O., Hube, B., 2004. *Candida albicans* proteinases and host pathogen interactions. *Cell Microbiology*. 6, 915–926.
- Nawangningrum, D., 2004. Kajian terhadap naskah kuna nusantara koleksi Fakultas Ilmu Pengetahuan Budaya Universitas Indonesia: Penyakit dan pengobatan ramuan tradisional. *Seri Sosial Humaniora (Social Humanities Series)*; Vol 8, No: 2.
- Pauli, A., 2006. Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils. *Medical Research Review*. 26, 223–268.



- Pratiwi, S.U.T., Legendijk, E.L., Weert, S. de, Hertiani, T., Idroes, R., Hondel, C.A.V.D., 2015. Effect of *Cinnamomum burmannii* Nees ex Bl. and *Massoia aromatica* Becc. essential oils on planktonic growth and biofilm formation of *Pseudomonas aeruginosa* and *Staphylococcus aureus* In Vitro. *International Journal of Applied Research in Natural Products.* 8, 1–13.
- Rali, T., Wossa, S.W., Leach, D.N., 2007. Comparative chemical analysis of the essential oil constituents in the bark, heartwood and fruits of *Cryptocarya massoy* (Oken) Kosterm. (Lauraceae) from Papua New Guinea. *Molecul. Basel Switz.* 12, 149–154.
- Ramage, G., Saville, S.P., Thomas, D.P., López-Ribot, J.L., 2005. *Candida* biofilms: an update. *Eukaryot. Cell* 4, 633–638.
- Samaranayake, L.P., Fidel, P.L., Naglik, J.R., Sweet, S.P., Teanpaisan, R., Coogan, M.M., Blignaut, E., Wanzala, P., 2002. Fungal infections associated with HIV infection. *Oral Disease. Suppl* 2, 151–160.
- Sangetha, S., Zuraini, Z., Suryani, S., Sasidharan, S., 2009. In situ TEM and SEM studies on the antimicrobial activity and prevention of *Candida albicans* biofilm by *Cassia spectabilis* extract. *Micron (Oxford England. 1993)* 40, 439–443.
- Schell, R.E., 1993. Proton permeability of renal membranes: influence of amphotericin B. *Nephron.* 63, 481.
- Sheppard, D., Lampiris, H.W., 2007. *Antifungal Agents Basic & Clinical Pharmacology*, 12e. Access Pharmacy. *McGraw-Hill Medical.* 3256.
- Silva, M.G.V., Vieira, I.G.P., Mendes, F.N.P., Albuquerque, I.L., dos Santos, R.N., Silva, F.O., *et al.*, 2008. Variation of ursolic acid content in eight *Ocimum* species from Northeastern Brazil. *Molecules Basel Switz.* 13, 2482–2487.
- Subroto, H.M.& M.A., 2006. *Gempur Penyakit dengan Minyak Herbal Papua*, 6. Agro Media. 25-37.
- Sudbery, P., Gow, N., Berman, J., 2004. The distinct morphogenic states of *Candida albicans*. *Trends Microbiology.* 12, 317–324.
- Soegihardjo, C.J., 1990, Masoyi (*Massoia aromatic* Becc.) dan Daun jantan (*Coleusamboinicus* Lour.) dengan teknik kultur jaringan, *Laporan Penelitian*,
Lembaga Penelitian UGM, Yogyakarta.
- Sukandar, E.Y., Andrajati, R., Sigit, J., Setiadi, A., Kusnandar, 2008. *ISO Farmakoterapi*. PT. ISFI Penerbitan, Jakarta, Indonesia. 250-255.
- Tashiro, M., Kimura, S., Tateda, K., Saga, T., Ohno, A., Ishii, Y., *et al.*, 2012. Pravastatin inhibits farnesol production in *Candida albicans* and improves



- survival in a mouse model of systemic candidiasis. *Medical Mycology*. 50, 353–360.
- Tietz, H.-J., 2010. Treatment of chronic vulvovaginal candidiasis with posaconazole and ciclopiroxolamine. *Health*. 2, 513–518.
- Tisserand, R., Young, R., 2014. *Essential Oil Safety. A Guide for Health Care Professionals* - Second Edition 16478-16479.
- Tisserand, R., Young, R., 2013. *Essential Oil Safety: A Guide for Health Care Professionals. Elsevier Health Sciences*. 16175-16187.
- Tiwari, V.K., Mishra, B.B., 2011. Opportunity, challenge and scope of natural products in medicinal chemistry. *Research Signpost*. Trivandrum, India. 107, 382-425.
- Tortora, G.J., Funke, B.R., Case, C.L., 2004. *Microbiology An Introduction 8th Edition, Benjamin-Cummings Publisher*. 567-722.
- Warena, A.J., Kauffman, S., Sherrill, T.P., Becker, J.M., Konopka, J.B., 2003. *Candida albicans* septin mutants are defective for invasive growth and virulence. *Infection Immunology*. 71, 4045–4051.
- Wilson, L.S., Reyes, C.M., Stolpman, M., Speckman, J., Allen, K., Beney, J., 2002. The direct cost and incidence of systemic fungal infections. *Value Health Journal International Social Pharmacoeconomics Outcomes Research*. 5, 26–34.
- Wingard, J.R., Leather, H., 2004. A new era of antifungal therapy. *Biology Blood Marrow Transplant*. 10, 73–90.